Crowley Fionnuala, Fitzgerald Bailey G, Bhardwaj Aarti S, Siraj Irine, Smith Cardinale
Department of Internal Medicine, Mount Sinai Morningside West, New York, New York.
Division of Hematology/Oncology, Mount Sinai Hospital, New York, New York.
JTO Clin Res Rep. 2021 Dec 4;3(1):100260. doi: 10.1016/j.jtocrr.2021.100260. eCollection 2022 Jan.
Osimertinib is the standard of care for the first-line treatment of -mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.
奥希替尼是治疗EGFR突变的非小细胞肺癌（NSCLC）一线治疗的标准药物。我们报告了一例52岁女性患者，因使用奥希替尼治疗而发生危及生命的肌病。此前文献中曾有少数几例关于肌炎的报道；然而，均未出现像本病例中所见的危及生命的口咽和呼吸肌无力情况。在与其他经CYP3A4系统代谢的药物同时使用奥希替尼时应谨慎，并且有必要持续开展工作以识别有严重反应风险的患者。应考虑将常规监测肌酐磷酸激酶作为肿瘤治疗管理的一部分。
